Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if treatment with a drug called fenofibrate, which is a PPAR-alpha agonist and controls how the heart metabolizes fats, will reverse the age-related decline in cardiac fat metabolism and mechanical function.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Aging (NIA)
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• Aged 60-75 or 21-35

• Normal glucose tolerance test

• Normal plasma fasting lipid panel (fasting total cholesterol less than 220 mg/dL)

• Normal rest/stress echocardiogram

• BMI (body mass index) less than 30 kg/m2

• Must be sedentary (active, but do not engage in regular exercise or jobs that require strenuous exertion)

Exclusion Criteria:

• Coronary artery disease

• High blood pressure

• Current smoker

• Diabetes mellitus

• Cardiovascular disease (signs and symptoms of any kind)

• Pregnant or breastfeeding